Head-to-head · Cost-Efficiency Index
No BS RX vs REMEVi
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
No BS RX
Someone who wants every term and every dose level comparable without starting an intake to see a price.
Visit No BS RXREMEVi
Cost-first shoppers who want bilingual, LegitScript-certified compounded GLP-1.
Visit REMEViThe verdict
No BS RX takes it, leading the Cost-Efficiency Index 82 to 80. Twenty-four prices on one public page, four dispensing pharmacies named with street addresses, and a no-intro-rate promise the arithmetic on its own page supports. REMEVi still earns a B− — Cost-first shoppers who want bilingual, LegitScript-certified compounded GLP-1.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs No BS RX.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | No BS RX | REMEVi |
|---|---|---|
| Cost-Efficiency Index | 82/100 | 80/100 |
| Semaglutide / mo | $179/mo month-to-month; a separate low-dose program runs $140 | $219/mo |
| Tirzepatide / mo | $249/mo month-to-month; a separate low-dose program runs $140 | $319/mo |
| Semaglutide / yr (modeled) | $2,148 | $2,628 |
| Tirzepatide / yr (modeled) | $2,988 | $3,828 |
| Coverage | Not disclosed | All 50 states |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #28 | #33 |
No BS RX
82/100Where the value is
- Names four dispensing pharmacies with street addresses and telephone numbers — Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx
- "No Fake Intro Rate — the price on the page is the ongoing program price" is a named commitment, and the $140 in its hero really is a month-to-month rate
- Every program row prints "503A pharmacy fulfillment" and "No dose-based price changes" on the table itself
The tradeoffs
- The same $409 twelve-week block appears under three different monthly rates — an $11 saving against one and a $128 saving against another, styled identically
- The low-dose programs stop at twelve weeks; only the standard programs carry 24- and 52-week rungs
REMEVi
80/100Where the value is
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
The tradeoffs
- The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.